Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Cassava Sciences Inc SAVA

Healthcare Biotechnology
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known... see more

Current News (NDAQ:SAVA)

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease

GlobeNewswire 6 days ago

Cassava Announces Agreement to Settle Securities Class Action Litigation

GlobeNewswire December 23, 2025

Cassava Reports Q3 2025 Financials Results and Provides Business Update

GlobeNewswire November 12, 2025

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Business Wire October 22, 2025

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

GlobeNewswire October 22, 2025

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire August 25, 2025

Cassava Reports Q2 2025 Financials Results and Provides Business Update

GlobeNewswire August 14, 2025

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

GlobeNewswire August 7, 2025

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

GlobeNewswire August 4, 2025
View More News ››

Opinion & Analysis (NDAQ:SAVA)

Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data

Streetwise Reports June 4, 2020

Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data

Streetwise Reports December 9, 2019

Three shots on goal in Q4/16 for DURECT Corp.

The Life Sciences Report September 8, 2016

Drug pricing, presidential politics, and three biotechs with promise

The Life Sciences Report April 13, 2016

From acorns mighty trees can grow: Laidlaw's Jim Molloy on budding small-cap biotechs

The Life Sciences Report March 16, 2016

Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

The Life Sciences Report March 11, 2016
View More Opinion ››

Bullboard Posts (NDAQ:SAVA)

Buy buddy buy.

Otherwise FOMO
coolfooldumbguy - September 23, 2025

Strong Fundamentals in $SAVA and $BOLT.CN

$SAVA’s innovative biotech pipeline positions it as a leader in addressing critical neurodegenerative diseases. Solid cash reserves...
TradeVision2001 - November 25, 2024

SAVA....and The Shorts win

Bad News for Bonzo the Bagholder
Iseneschal - November 25, 2024

SAVA Borrow Fee Sky High with 50% Float Sold Short Cover

SAVA Borrow Fee Sky High with 50% Float Sold Short Cover Buy to Cover Shorty
10QKing - November 25, 2024

SAVA 47% Float Sold Short Squeeze them force them to cover c

SAVA 47% Float Sold Short Squeeze them force them to cover currently down huge
10QKing - November 25, 2024

Cassava Sciences, Inc. (NASDAQ:SAVA): A Promising Alzheimer&

http://beyondspx.com/2024/08/02/cassava-sciences-inc-nasdaqsava-a-promising-alzheimers-candidate-facing-challenges/
MikeTester - August 3, 2024
View more Bullboard ››

NU E Power Corp

NU E Power Corp

NU E Power Corp. develops, owns, and operates renewable energy projects in Canada. It is involved in the development of solar ...
View More »

Podcasts